140 related articles for article (PubMed ID: 32721848)
1. Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?
Plodkowski AJ; Araujo-Filho JAB; Simmers CDA; Girshman J; Raj M; Zheng J; Rimner A; Ginsberg MS
Clin Imaging; 2021 Jan; 69():133-138. PubMed ID: 32721848
[TBL] [Abstract][Full Text] [Related]
2. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of
Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
[TBL] [Abstract][Full Text] [Related]
5. Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer.
Rajpara RS; Schreibmann E; Fox T; Stapleford LJ; Beitler JJ; Curran WJ; Higgins KA
Radiat Oncol; 2014 Aug; 9():187. PubMed ID: 25154893
[TBL] [Abstract][Full Text] [Related]
6. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of computed tomography texture features in non-small cell lung cancers treated with definitive concomitant chemoradiotherapy.
Ahn SY; Park CM; Park SJ; Kim HJ; Song C; Lee SM; McAdams HP; Goo JM
Invest Radiol; 2015 Oct; 50(10):719-25. PubMed ID: 26020832
[TBL] [Abstract][Full Text] [Related]
8. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
[TBL] [Abstract][Full Text] [Related]
9. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Dunlap NE; Yang W; McIntosh A; Sheng K; Benedict SH; Read PW; Larner JM
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1071-7. PubMed ID: 22898383
[TBL] [Abstract][Full Text] [Related]
10. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
[TBL] [Abstract][Full Text] [Related]
11. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
13. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.
Lim HJ; Lee HY; Lee KS; Han J; Kwon OJ; Park K; Ahn YC; Kim BT; Shim YM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):77-85. PubMed ID: 25374409
[TBL] [Abstract][Full Text] [Related]
15. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
16. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
[TBL] [Abstract][Full Text] [Related]
19. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
20. Assessment of recurrence of non-small cell lung cancer after therapy using CT and Integrated PET/CT.
Opoka L; Szołkowska M; Podgajny Z; Kunikowska J; Barańska I; Błasińska-Przerwa K; Jakubowska L; Rudziński P; Bestry I; Roszkowski-Śliż K
Pneumonol Alergol Pol; 2013; 81(3):214-20. PubMed ID: 23609428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
